Comparison of outpatient visit patterns for renal anemia in patients with chronic kidney disease

Comparison of outpatient visit frequency, visit duration, and drug-related costs between HIF-PH inhibitors and erythropoiesis-stimulating agents for renal anemia in patients with chronic kidney disease: a single-center retrospective observational study - CKD Anemia Visit Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061224

Enrollment

300

Registered

2026-04-11

Start date

2026-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-dialysis chronic kidney disease (CKD) who attended the outpatient department of the Department of Nephrology and Endocrinology at the University of Tokyo Hospital between January 1, 2022 and December 31, 2025, and who received or were prescribed erythropoiesis-stimulating agents (ESAs) or HIF-PH inhibitors during the observation period.

Exclusion criteria

Exclusion criteria: Patients who were considered inappropriate for inclusion in the study by the investigators, or who declined the use of their information for research purposes.

Design outcomes

Primary

Measure	Time frame
Outpatient visit frequency (number of visits per year), outpatient visit duration, and drug-related costs based on drug prices.	—

Countries

Japan

Contacts

Public ContactSayako Maruno

The University of Tokyo Hospital Department of Nephrology and Endocrinology

smaruno-tky@g.ecc.u-tokyo.ac.jp03-3815-5411

Outcome results